| P50 | author | Edward K Geissler | Q114400579 |
| P2093 | author name string | Hans J Schlitt | |
| | Karl-Walter Jauch | |
| | Markus Guba | |
| | Gudrun E Koehl | |
| | Markus Steinbauer | |
| | Axel Doenecke | |
| | Evelyn Neppl | |
| P2860 | cites work | Angiogenesis in health and disease | Q29614541 |
| | Rapamycin in transplantation: a review of the evidence | Q31789323 |
| | Mechanism of action of the immunosuppressant rapamycin | Q40965429 |
| | mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer | Q42660087 |
| | FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation | Q43600259 |
| | Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor | Q43873032 |
| | Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy | Q44013375 |
| | Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies | Q47954202 |
| P433 | issue | 1 | |
| P921 | main subject | sirolimus | Q32089 |
| | angiogenesis inhibitor | Q574834 |
| P304 | page(s) | 89-94 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Transplant International | Q15762140 |
| P1476 | title | Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. | |
| P478 | volume | 18 | |